Diabetes Mellitus Remission in Patients with BMI > 50 kg/m2 after Bariatric Surgeries: A Real-World Multi-Centered Study

Introduction Type 2 diabetes mellitus (T2DM) is a common comorbidity associated with obesity, particularly in patients with body mass index (BMI) >= 50 kg/m(2). We aim to study real-world T2DM long-term remission in patients with BMI >= 50 kg/ m(2) following Roux-En-Y gastric bypass (RYGB) or sleeve gastrectomy (SG). Methods This was a retrospective study of the electronic medical records of all patients with BMI >= 50 kg/m(2), T2DM, and have undergone RYGB or SG at three tertiary referral centers in the United States. We assessed the change in T2DM outcomes after bariatric surgery using a matched paired t-test for continuous variables and Bowker and Pearson test for categorical variables. We performed a multivariate logistic regression to determine predictors of remission. Results A total of 279 patients with T2DM (65% females, mean age 51.0 +/- 11.7 years, 89% white, BMI 56.6 +/- 5.9 kg/m(2)) were analyzed. Long-term T2DM remission (>= 5 years) was demonstrated in 47% of patients. The duration of T2DM (p < 0.0001), number of T2DM medications (p = 0.003) and weight loss (p = 0.048) were the only independent factors for long-term T2DM remission. Conclusions In this cohort of patients with BMI >= 50 kg/m(2), RYGB and SG demonstrated significant and similar long-term T2DM remission rates and weight loss outcomes.

Automated summary

In this study, the long-term remission of type 2 diabetes (T2DM) in patients with BMI >= 50 kg/m(2) who underwent Roux-En-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) was investigated. Among 279 T2DM patients who underwent RYGB or SG, 47% achieved long-term remission (>= 5 years), with duration, medication usage, and weight loss being identified as independent factors for long-term remission.